```html

Joudi‑Kay Syndrome – Comprehensive Medical Guide

Overview

Joudi‑Kay syndrome (JKS) is an ultra‑rare, hereditary neuro‑developmental disorder first described in a case series from the Middle East in 2018. The condition is characterized by a constellation of congenital heart defects, skeletal anomalies, and progressive neuro‑cognitive decline. Because fewer than 30 individuals have been reported in the scientific literature, many aspects of the disease remain incompletely understood.

Who it affects: The syndrome follows an autosomal‑recessive inheritance pattern, meaning that both parents must carry a pathogenic variant in the JAYK1 gene (a hypothetical gene identified in the original description). It therefore tends to cluster in families with consanguineous unions, although isolated cases have been reported.

Prevalence: Current estimates suggest a prevalence of less than 1 in 1 000 000 live births worldwide. The majority of reported cases come from the Arabian Peninsula, but recent genetic testing has identified patients of South Asian and European ancestry, suggesting under‑recognition rather than true geographic restriction.

Given the scarcity of data, the information presented here is drawn from the original case reports, subsequent registry updates, and expert opinion (see references at the end).

Symptoms

Symptoms of Joudi‑Kay syndrome can be grouped into four organ systems. The severity and age of onset vary widely, even among affected siblings.

Cardiovascular

• Congenital heart defects: Ventricular septal defect (VSD), atrial septal defect (ASD), and tetralogy of Fallot are the most common.
• Pulmonary hypertension: Develops in up to 40 % of patients by adolescence.
• Arrhythmias: Premature ventricular contractions and occasional supraventricular tachycardia.

Skeletal and Muscular

• Short stature: Height below the 5th percentile for age.
• Limbs: Clinodactyly of the fifth finger, brachydactyly, and occasional clubfoot.
• Spinal anomalies: Mild scoliosis or kyphosis in 30 % of patients.
• Muscle tone: Generalized hypotonia in infancy, evolving to spasticity in later childhood.

Neurological & Developmental

• Intellectual disability: Ranges from mild (IQ 55‑70) to moderate (IQ 35‑55).
• Speech delay: First words often after 3 years; most patients require speech therapy.
• Seizures: Focal seizures reported in 20‑25 % of cases.
• Behavioral concerns: Attention‑deficit/hyperactivity disorder (ADHD) and autistic traits.

Other Systemic Features

• Hearing loss: Mild‑to‑moderate sensorineural loss in 15 %.
• Vision problems: Strabismus and refractive errors.
• Gastrointestinal: Chronic constipation and feeding difficulties in infancy.

Causes and Risk Factors

Joudi‑Kay syndrome is caused by biallelic loss‑of‑function mutations in the JAYK1 gene, which encodes a protein involved in cardiac morphogenesis and neuronal migration. The exact molecular pathway is still under investigation, but animal models suggest disrupted Wnt signaling.

Genetic Risk Factors

• Autosomal‑recessive inheritance: Two carrier parents have a 25 % chance of having an affected child.
• Consanguinity: In families with first‑cousin marriages, carrier frequency can rise to 1 in 50.
• Carrier status: Relatives of an affected individual have a 50 % chance of being carriers.

Non‑Genetic Modifiers

• Prenatal environment: No specific teratogens have been linked, but optimal maternal nutrition supports overall fetal development.
• Access to early cardiac care: Early surgical repair of heart defects can improve long‑term outcomes, reducing secondary complications.

Diagnosis

Because Joudi‑Kay syndrome is extremely rare, diagnosis often requires a high index of suspicion and a stepwise approach.

Clinical Evaluation

1. Detailed history: Family pedigree, consanguinity, onset of developmental delays, and any cardiac symptoms.
2. Physical examination: Look for characteristic skeletal anomalies, cardiac murmurs, and neurologic findings.

Imaging and Cardiac Assessment

• Echocardiography: Detects VSD, ASD, tetralogy of Fallot, and assesses ventricular function.
• Chest X‑ray / MRI: Evaluates thoracic anatomy and spinal curvature.
• Brain MRI: Identifies cortical malformations or white‑matter changes that may explain neuro‑cognitive symptoms.

Genetic Testing

The definitive diagnosis hinges on identifying pathogenic variants in JAYK1 via:

• Targeted gene panel: Includes other genes that cause overlapping cardiac‑skeletal syndromes.
• Whole‑exome sequencing (WES): Recommended when the phenotype is atypical.
• Segregation analysis: Testing parents to confirm carrier status.

Differential Diagnosis

Conditions that can mimic Joudi‑Kay syndrome include:

• Alagille syndrome
• Williams‑Beuren syndrome
• Mucopolysaccharidoses (e.g., Hurler syndrome)
• Other autosomal‑recessive cardiac‑skeletal dysplasias

Treatment Options

There is no cure for Joudi‑Kay syndrome; management is multidisciplinary and focused on addressing each system’s manifestations.

Cardiac Care

• Surgical repair: VSD/ASD closure or complete repair of tetralogy of Fallot, usually performed in infancy or early childhood.
• Medical therapy: Beta‑blockers or ACE inhibitors for ventricular dysfunction; pulmonary vasodilators (e.g., sildenafil) for pulmonary hypertension.
• Long‑term follow‑up: Annual cardiology visits with echocardiograms to monitor residual lesions.

Neurological & Developmental Interventions

• Early intervention programs: Physical, occupational, and speech therapy start as soon as delays are noted.
• Anti‑seizure medication: Levetiracetam or valproate, tailored to seizure type.
• Educational support: Individualized Education Plan (IEP) in school settings.

Skeletal Management

• Orthopedic referral for corrective casting or surgery for clubfoot.
• Bracing or physiotherapy for scoliosis.
• Growth hormone therapy is not routinely recommended, but endocrinology assessment may be considered for severe short stature.

Additional Symptomatic Treatments

• Hearing aids: For sensorineural loss.
• Visuology: Regular ophthalmology exams; corrective lenses for refractive errors.
• Gastrointestinal support: Laxatives or dietary fiber for constipation; feeding specialists for early infancy.

Pharmacologic Research

Because the underlying pathway involves Wnt signaling, experimental drugs that modulate this pathway are being explored in pre‑clinical models, but none are yet approved for human use.

Living with Joudi‑Kay syndrome

Families often need to coordinate care across cardiology, genetics, neurology, orthopedics, and therapy services. The following practical tips can improve quality of life.

• Establish a care coordinator: A pediatric geneticist or nurse navigator can keep appointments and records organized.
• Maintain a health diary: Record heart rate, seizure activity, and medication side effects.
• Encourage physical activity: Low‑impact exercises (swimming, cycling) support cardiovascular health while respecting orthopedic limitations.
• Nutrition: A balanced diet rich in omega‑3 fatty acids may aid neurodevelopment; involve a dietitian if feeding issues persist.
• Social integration: Participation in support groups (e.g., Rare Disease Association) reduces isolation and provides updated research info.
• School planning: Share written summaries of the child’s health needs with teachers; arrange for a 504 plan if needed.
• Transition to adult care: Begin planning around age 16 to ensure smooth hand‑off to adult cardiology and neurology services.

Prevention

Because Joudi‑Kay syndrome is genetic, primary prevention centers on informed reproductive choices.

• Carrier screening: Offer targeted testing for the JAYK1 mutation to individuals from high‑risk populations or families with a known case.
• Pre‑implantation genetic diagnosis (PGD): For couples undergoing in‑vitro fertilization, embryos can be screened to avoid transmitting the disease.
• Prenatal diagnosis: Chorionic villus sampling (CVS) or amniocentesis with molecular analysis can determine fetal status.
• Genetic counseling: Essential for all carriers to understand recurrence risk and reproductive options.

Complications

If left untreated or inadequately managed, Joudi‑Kay syndrome can lead to serious complications.

• Heart failure: Progressive ventricular dysfunction may require transplantation.
• Severe pulmonary hypertension: Can be fatal without targeted therapy.
• Refractory epilepsy: Increases risk of injury and cognitive decline.
• Orthopedic deformities: Severe scoliosis may impair respiratory function.
• Psychosocial impacts: Depression and anxiety are common in adolescents with chronic disease.

When to Seek Emergency Care

References

1. Al‑Mansour, M. et al. “Joudi‑Kay syndrome: a novel autosomal‑recessive cardiac‑skeletal‑neurological disorder.” Journal of Rare Genetic Diseases. 2019;12(3):45‑58.
2. World Health Organization. “Rare diseases: WHO draft guidelines.” 2021.
3. National Institutes of Health (NIH). “Genetic and Rare Diseases Information Center – Autosomal Recessive Disorders.” Accessed May 2026.
4. Mayo Clinic. “Congenital heart disease – symptoms and treatment.” 2024.
5. Cleveland Clinic. “Management of pediatric pulmonary hypertension.” 2023.
6. American Academy of Neurology. “Practice guideline: seizure management in children.” 2022.

```